Orexigen Therapeutics (OREX)
Orexigen Therapeutics Price / Sales Ratio: 65.80
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OREX Price / Sales Ratio Rankings
| Overall | 0th percentile | 4291 of 4323 |
| Sector | 4th percentile | 428 of 450 in Healthcare |
| Industry | 2nd percentile | 36 of 37 in Drug Manufacturers - Other |
OREX Price / Sales Ratio Range, Past 5 Years
| Minimum | 19.66 | Dec 2011 |
| Maximum | 5197 | Sep 2009 |
| Average | 2150 |
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these OREX related companies
OREX News
$ARNA rebounds after share offering last week at $5.50 $OREX $VVUS http://stks.co/3vPY
about 5 days ago by EPS_MomentuM
about 5 days ago by EPS_MomentuM
RT @Bleedblue: RT @newkidontheblock FDA follows Adcom rec 80 percent. $orex anyone? Was the 20% it DOES happen.
about 11 days ago by DutchFanBoy
about 11 days ago by DutchFanBoy
$ARNA close above 7$ will be very bullish as market wants a turn around Tuesday $VVUS $OREX $$
about 11 days ago by peterumble
about 11 days ago by peterumble
$ARNA looks stronger day by day means more upside to come yet, a good day will break 8$ this week $VVUS $OREX $$
about 11 days ago by peterumble
about 11 days ago by peterumble
@Bleedblue don't know about dates $orex i do TA mostly very little biotech $study but have a hunch from what i've read it is safer of the 2
about 12 days ago by Good2go
about 12 days ago by Good2go
@Bleedblue agree & the reason that $orex will follow $arna & 1 day possibly have the preferred drug (fda willing that is).
about 12 days ago by Good2go
about 12 days ago by Good2go
@DrNick This is strange, seeing $OREX only has two products in the pipeline... Kind of early move, eh!? ;-)
about 12 days ago by mitrado
about 12 days ago by mitrado
@DrNick $orex nice, thanks for the link. bought some today. not in $arna
about 12 days ago by Good2go
about 12 days ago by Good2go
$OREX looked like a strong push there but it faded into craptasticness.
about 12 days ago by Captain_Power
about 12 days ago by Captain_Power
Arena and Orexigen Compete to Bring First Weight Loss Drug to Market in Nearly 13 Years
May 14, 8:20AM Marketwire
May 14, 8:20AM Marketwire
Unusual 11 Mid-Day Movers 05/11: (ARNA) (RPRX) (GWAY) Higher; (ADY) (AMOT) (ASYS) Lower
May 11, 1:56PM Street Insider
May 11, 1:56PM Street Insider
Bank of America: Key Takeaways from Orexigen Therapeutics' Management Meetings
Apr 11, 10:27AM Benzinga
Apr 11, 10:27AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OREX | 3.33 | -0.10 | -2.92% | 225.57M |
| ORCL | 26.14 | +0.02 | +0.08% | 131.38B |
| OPTR | 15.32 | -0.28 | -1.79% | 716.21M |
| OMG | 18.10 | +0.18 | +1.00% | 585.17M |
| OMEX | 3.33 | +0.14 | +4.39% | 243.56M |
| OMCL | 13.71 | -0.06 | -0.44% | 459.15M |
| OMC | 49.78 | -0.32 | -0.64% | 13.58B |
| OLP | 18.56 | -0.26 | -1.38% | 273.39M |
| OLCB | 1.10 | +0.09 | +8.91% | 21.69M |
| OIB | 7.81 | +0.03 | +0.45% |
